1. Chris Chavez, Jay Gantz, Que Anh Nguyen Genigma

2. Company Info Founded in December 2002 Located in Newton, MA Three Employees –George Berbeco, Chairman and CEO –Adam Brady-Myerov, VP Sales and Marketing –Kevin Daly, Director of Science Product: Absolute Quenchers

3. Quenchers- What are they? Biological probe: on/off switch

4. Market Potential Total Market is ~$40-50 million Expected revenue for 2004 ~$3 million Expected margins ~80% 50% growth per year

5. Company History 3 Original Founders MIT 50K Competition Stanford Business Plan Genigma Formed 2000 2002 EyeGenRed Absolute Quenchers (AbQ)

6. Funding Structure Venture Capital Investors George Berbeco

7. The People of Genigma George Berbeco, Chairman and CEO –Lifetime entrepreneur –Holds over 20 issued US and foreign patents –M.S. and B.S. in Chemical Engineering from MIT –Became involved with Genigma through MIT 50k competition

8. The People of Genigma Adam Brady-Myerov, Vice President, Sales and Marketing –B.A. from Washington University in St. Louis –M.B.A. from M.I.T./ Sloan –12+ years of experience in biotech and life sciences encompassing research, business development and product management –Heard about Genigma as a MIT 50k winner

9. The People of Genigma Kevin Daly, Director of Science –M.A. and B.A. in Chemistry from BU –8+ years of chemical synthesis experience in areas of biotech and research pharma –Holds several patents in chemical synthesis

10. Product Development Flawed Product Brainstorming Funneling of ideas (feasibility, market potential, etc…) Prioritize product ideas Quenchers Market Research Absolute Quencher

11. Marketing Best not cheapest Current Strategy –Large direct mailing with discount offer Supply chain placement –Strategic placement between customer and supplier –Future: Transparent

12. Competitors Metabion –Black Hole Quencher –current market leader Epoch Biosciences –Eclipse Quencher –packaged with minor groove binders

13. Vision Genigma aims to become the market leader in the quencher industry Integrate themselves into the research supply chain.

14. Future of Genigma Products down the line –Antibodies –Proteins Successful but not the next Pfizer

15. Questions? Thanks to George, Adam and Kevin